Compounds > bicalutamide

bicalutamide and Ductal Carcinoma

bicalutamide has been researched along with Ductal Carcinoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Allen, C; Ball, R; Dickinson, L; Freeman, A; Giganti, F; Haider, A; Moore, CM; Ramachandran, N; Sridhar, A; Tandogdu, Z1
Jaspers, HC; Mattijssen, V; Schoffelen, R; Slootweg, PJ; van der Graaf, WT; van Herpen, CM; Verbist, BM1

Other Studies

2 other study(ies) available for bicalutamide and Ductal Carcinoma

ArticleYear
Mixed acinar and macrocystic ductal prostatic adenocarcinoma.
    The Lancet. Oncology, 2021, Volume: 22, Issue:1

    Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Carcinoma, Ductal; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Complex and Mixed; Neoplasms, Cystic, Mucinous, and Serous; Nitriles; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome

2021
Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-01, Volume: 29, Issue:16

    Topics: Anilides; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Ductal; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Nitriles; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Tosyl Compounds

2011